ROSGQ (Rosetta Genomics) Common Stock: $4.90 Mil (As of Jun. 2017)


What is Rosetta Genomics Common Stock?

Rosetta Genomics ROSGQ -99.00% Common Stock is $4.90 Mil as of Jun. 2017.

Rosetta Genomics's quarterly common stock increased from Jun. 2016 ($3.25 Mil) to Dec. 2016 ($3.44 Mil) and increased from Dec. 2016 ($3.44 Mil) to Jun. 2017 ($4.90 Mil).

Rosetta Genomics's annual common stock increased from Dec. 2014 ($1.83 Mil) to Dec. 2015 ($3.19 Mil) and increased from Dec. 2015 ($3.19 Mil) to Dec. 2016 ($3.44 Mil).

Rosetta Genomics Common Stock Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Common Stock Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.38 1.61 1.83 3.19 3.44

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 3.19 3.25 3.44 4.90

Rosetta Genomics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $4.90 Mil mean?
Rosetta Genomics (ROSGQ) has a Common Stock of $4.90 Mil as of Jun. 2017. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Common Stock too high?
Rosetta Genomics' current Common Stock is $4.90 Mil.
How does Rosetta Genomics' Common Stock compare to TEAR and IDTA?
Rosetta Genomics' Common Stock of $4.90 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Diagnostics & Research company?
A good Common Stock depends on the Medical Diagnostics & Research industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current Common Stock is $4.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Common Stock of $4.90 Mil. The current Common Stock is $4.90 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Common Stock is $4.90 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.